Media Contacts:

Asia Pacific

Melanie Kerin
Mobile: +61 (0) 417 436 329

Seqirus news releases

Seqirus news releases

Seqirus and Richter sign a license agreement for the commercialisation of a novel treatment for schizophrenia in Australia and New Zealand
24 May 2019 News Release

Seqirus Pty Ltd (Seqirus) and Gedeon Richter Plc (Richter) today announced the signing of an exclusive license agreement to commercialise a novel antipsychotic in Australia and New Zealand.

New PNG Snakebite Project to Improve Access to Antivenoms
17 Apr 2018 News Release

The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management system.

Australians unprepared for potential dangers of venomous creatures this summer
27 Nov 2017 News Release

Seqirus launches #NoStingsSummer campaign encouraging Aussies to take care and watch out for bites and stings this summer

Seqirus launches first over-the-counter offering, Nervoderm®
03 Oct 2017 News Release

Seqirus has entered the over-the-counter market for the first time with a new Schedule 2, medicated patch, Nervoderm®.

Seqirus Manufacturing Director Recognised at 2017 Women in Industry Awards
23 Jun 2017 News Release

Lisa Lamb, Manufacturing Director for Products of National Significance at biopharmaceutical company Seqirus has been named winner of the Manufacturing Excellence category at the 2017 Women in Industry Awards hosted in Melbourne on Thursday 22 June.

Afluria Quad™ – a four strain flu vaccine manufactured in Australia is now available
26 Apr 2017 News Release

A quadrivalent flu vaccine manufactured by Seqirus locally in Melbourne, Australia is available for the 2017 Australian flu season for adults aged 18 years and older.